SCHEMBL3200155

SCHEMBL3200155

Nc1ccc(C(=O)Nc2nccs2)cc1Cl

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 9/20 0.66
NPC1 O15118 9/20 0.66
SMN1; SMN2 Q16637 4/20 0.66
LMNA P02545 3/20 0.66
RECQL P46063 1/20 0.66
L3MBTL1 Q9Y468 1/20 0.66
GCK P35557 1/20 0.64
MAPK1 P28482 3/20 0.63
PIK3CD O00329 1/20 0.63
PIK3C2B O00750 1/20 0.63
AURKA O14965 1/20 0.63
PIK3C2G O75747 1/20 0.63
CDK1 P06493 1/20 0.63
CDK4 P11802 1/20 0.63
CCND1 P24385 1/20 0.63
CDK2 P24941 1/20 0.63
MAPK3 P27361 1/20 0.63
CCND3 P30281 1/20 0.63
MAPK4 P31152 1/20 0.63
PIK3CA P42336 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2956673 0.87 RAB9A (0.71) RAB9ANPC1SMN1; SMN2LMNARECQL
SCHEMBL4297087 0.84 MAPK1 (0.61) RAB9ANPC1SMN1; SMN2LMNARECQL
SCHEMBL3199881 0.84 RAB9A (0.66) RAB9ANPC1SMN1; SMN2LMNARECQL
SCHEMBL3190864 0.84 RAB9A (0.66) RAB9ANPC1SMN1; SMN2LMNARECQL
SCHEMBL3206087 0.84 RAB9A (0.66) RAB9ANPC1SMN1; SMN2LMNARECQL
SCHEMBL4297480 0.81 RAB9A (0.61) RAB9ANPC1SMN1; SMN2LMNARECQL
SCHEMBL3188014 0.81 RAB9A (0.79) RAB9ANPC1SMN1; SMN2LMNARECQL
SCHEMBL28801036 0.80 NPC1 (0.72) RAB9ANPC1SMN1; SMN2LMNARECQL
SCHEMBL9963854 0.80 RAB9A (0.89) RAB9ANPC1SMN1; SMN2LMNARECQL
SCHEMBL3200814 0.80 NPC1 (1.00) RAB9ANPC1SMN1; SMN2LMNARECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090247593-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES H. LUNDBECK A/S (DK) 2009-10-01 US claimed
EP-1803455-A1 N-thiazol-2-yl-benzamide derivatives H.Lundbeck A/S (DK) 2007-07-04 EP claimed
EP-1682129-B1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES LUNDBECK & CO AS H (DK) 2007-02-21 EP claimed
EP-1682129-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES H. LUNDBECK A/S (DK) 2006-07-26 EP claimed
US-20060154974-A1 N-thiazol-2-yl-benzamide derivatives H. LUNDBECK A/S (DK) 2006-07-13 US claimed
WO-2005039572-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES H. LUNDBECK A/S (DK) 2005-05-06 WO claimed
US-7674912-B2 Pro-drugs of N-thiazol-2-yl-benzamide derivatives H. LUNDBECK A/S (DK) 2010-03-09 US disclosed
US-20090247593-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES H. LUNDBECK A/S (DK) 2009-10-01 US disclosed
EP-1877391-A1 PRO-DRUGS OF N-THIAZOL-2YL-BENZAMIDE DERIVATIVES H. Lundbeck A/S (DK) 2008-01-16 EP disclosed
EP-1803455-A1 N-thiazol-2-yl-benzamide derivatives H.Lundbeck A/S (DK) 2007-07-04 EP disclosed
EP-1682129-B1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES LUNDBECK & CO AS H (DK) 2007-02-21 EP disclosed
CN-1870996-A N-thiazol-2-yl-benzamide derivatives LUNDBECK & CO AS H (DK) 2006-11-29 CN disclosed
US-20060264485-A1 Pro-drugs of N-thiazol-2-yl-benzamide derivatives H. LUNDBECK A/S (DK) 2006-11-23 US disclosed
WO-2006114093-A1 PRO-DRUGS OF N-THIAZOL-2YL-BENZAMIDE DERIVATIVES H. LUNDBECK A/S (DK) 2006-11-02 WO disclosed
EP-1682129-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES H. LUNDBECK A/S (DK) 2006-07-26 EP disclosed
US-20060154974-A1 N-thiazol-2-yl-benzamide derivatives H. LUNDBECK A/S (DK) 2006-07-13 US disclosed
WO-2005039572-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES H. LUNDBECK A/S (DK) 2005-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247593-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES ADORA2A, ADORA3, ADORA1 RAB9A 2380/4885NPC1 1022/4885SMN1; SMN2 1617/4885
US-20060154974-A1 N-thiazol-2-yl-benzamide derivatives ADORA2A, ADORA3, ADORA1 RAB9A 2380/4885NPC1 1022/4885SMN1; SMN2 1617/4885
US-20060264485-A1 Pro-drugs of N-thiazol-2-yl-benzamide derivatives ADORA2A, ADORA2B, ADORA1 RAB9A 1524/4885NPC1 652/4885SMN1; SMN2 1680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.